Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Technique Detects Breaks in Mitochondrial DNA

By LabMedica International staff writers
Posted on 22 Apr 2019
The Splice-Break pipeline is a recently described technique that can detect and quantify mitochondrial DNA (mtDNA) deletions at a high level of resolution.

Deletions in the mitochondrial genome have been implicated in numerous human disorders that often display muscular and/or neurological symptoms due to the high-energy demands of these tissues. More...
Among these "mitochondrial myopathies" are Kearns–Sayre syndrome (KSS), Pearson Syndrome (PS), chronic progressive external ophthalmoplegia (CPEO), Leigh syndrome, and diabetes mellitus.

Investigators at the University of California, Irvine (USA) described a catalogue of 4,489 putative mtDNA deletions, including their frequency and relative read rate. To do this, they employed a combinatorial approach of mitochondria-targeted PCR, next-generation sequencing, bioinformatics, post-hoc filtering, annotation, and validation steps. Their bioinformatics pipeline incorporated MapSplice, an RNA-seq splice junction detection algorithm, to detect and quantify mtDNA deletion breakpoints rather than mRNA splices.

The investigators used their technique to analyze 93 samples from postmortem brain and blood. They found that the 4977-base pairs "common deletion" was neither the most frequent deletion nor the most abundant and that brain contained significantly more deletions than blood.

“Taken together, the pipeline will enable us to look in many brain regions for an accumulation of damage to mitochondria DNA for individuals with various psychiatric symptoms such as depression and psychosis. The ultimate use will be to test other more accessible samples such as blood, saliva, or cerebrospinal fluid from patients to estimate the damage to mitochondria, and quickly identify those individuals who may benefit from drugs and other treatments that give a mitochondria boost and improve psychiatric symptoms,” said senior author Dr. Marquis P. Vawter, a researcher in the department of psychiatry and human behavior at the University of California, Irvine. “This technique allows us to use a single test to measure the accumulation of many types of these deletions and to determine an overall burden of these deletions upon mitochondria functions.”

The study was published in the March 14, 2019, online edition of the journal Nucleic Acids Research.

Related Links:
University of California, Irvine


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.